Neuroblastoma vaccine - MabVax/MSKCC

Drug Profile

Neuroblastoma vaccine - MabVax/MSKCC

Alternative Names: MV Neuro; MV-NB-02

Latest Information Update: 28 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuroblastoma

Most Recent Events

  • 06 Apr 2015 MabVax Therapeutics plans a phase II trial for Neuroblastoma (In children) in USA
  • 25 Sep 2014 Neuroblastoma vaccine - MabVax/MSKCC receives Orphan Drug status for Neuroblastoma in USA
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top